March Biosciences is dedicated to revolutionizing patient care by discovering and exploiting high-impact targets for cancer immunotherapy. Our lead asset, MB-105, is designed to treat relapse/refractory T-cell malignancies, currently with  no effective and curative alternative treatments 

Bioscience Programs

Bioscience Programs

CAR-T Therapy

Engineered T-cells expressing a chimeric antigen receptor are known as CAR T-cells. Compared to natural – cells, CAR T cells are engineered to detect specific target antigens on the surface of cancer cells, boosting the effectiveness of cancer cell killing by the immune system.

1. Collection of T cells:

by Leukapheresis procedure, to isolate T cells from a patient’s blood.

2. Genetic modification of T cells:

T cells are then genetically engineered in a laboratory to express the CAR, specifically designed to selectively recognize antigens on the cancer cells’ surface.

3. Expansion and activation of CAR T cells:

T cells are modified in the lab to express the CAR, multiplied to increase their numbers and activated to boost their anti-cancer activity.

4. Infusion of CAR T cells:

Following expansion and activation CAR-T cells are then infused back into the patient’s bloodstream intravenously.

This, allow CAR-T cells to circulate and recognize cancer cells expressing the target antigen.

Ongoing trial

Our lead asset, MB-105 is currently being evaluated in a Phase 1 clinical trial (NCT03081910) for T-cell lymphoma and T-cell acute lymphoblastic leukemia (TCL and T-ALL). Initial results have revealed promising signals of safety and efficacy for these patients, who otherwise have limited treatment options. Enrollment for this trial is ongoing.

News & Publications

Read more about how March Biosciences’ research has impacted the medical community.